Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cancer drug tested in people with advanced tumors

NCT ID NCT06457997

First seen Jan 31, 2026 · Last updated Jun 13, 2026 · Updated 18 times

Summary

This early study tested a new drug called PHN-010 in 26 people with advanced cancers like lung, colon, and ovarian cancer. The drug is designed to deliver a powerful treatment directly to cancer cells. The main goals were to check safety and find the right dose, but the study was stopped early.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • AdventHealth

    Orlando, Florida, 32804, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • NEXT - San Antonio

    San Antonio, Texas, 78229, United States

  • NEXT - Virginia

    Fairfax, Virginia, 22031, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • University of Washington/Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

Conditions

The condition(s) this trial relates to.

cancer carcinoma colonic neoplasm endometrium neoplasm lung neoplasm neoplasm ovarian cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.